晚期上皮性卵巢癌中间型减瘤术的最佳时机:一项来自ESME国家队列的回顾性研究
该回顾性研究基于法国国家数据库,纳入2011年1月至2016年12月新诊断并接受中间型减瘤术的上皮性卵巢癌患者928例,比较标准中间型减瘤术(3-4周期新辅助化疗后)与延迟中间型减瘤术(≥5周期后)的生存结局。倾向评分加权分析显示,标准组中位无进展生存期17.6个月 vs 延迟组11.5个月(HR=1.42,95%CI 1.22-1.67,p<0.0001),中位总生存期51.2个月 vs 44.3个月(HR=1.29,95%CI 1.06-1.56,p=0.0095);结论认为≥5周期新辅助化疗后行中间型减瘤术可能对生存有负面影响,手术目标为完全切除,不应在超过3-4周期新辅助化疗后进行。
要点
- 标准中间型减瘤术组中位无进展生存期17.6个月 vs 延迟组11.5个月(HR=1.42,p<0.0001)。
- 标准组中位总生存期51.2个月 vs 延迟组44.3个月(HR=1.29,p=0.0095)。
核心结论
- ≥5周期新辅助化疗后行中间型减瘤术似乎对患者生存有负面影响。
- 中间型减瘤术的目标是完全切除,不应在超过3-4周期新辅助化疗后进行。
研究设计与样本
- 回顾性研究,基于法国国家数据库(ESME),纳入2011年1月至2016年12月新诊断并接受中间型减瘤术的上皮性卵巢癌患者928例。
- 采用Cox模型比较无进展生存期和总生存期,并通过倾向评分逆概率治疗加权和匹配对分析校正混杂因素。
主要发现
- 中位随访49.0个月(95%CI 46.0-52.9)。
- 逆概率治疗加权分析:标准中间型减瘤术组中位无进展生存期17.6个月 vs 延迟组11.5个月(HR=1.42,95%CI 1.22-1.67,p<0.0001)。
- 逆概率治疗加权分析:标准组中位总生存期51.2个月 vs 延迟组44.3个月(HR=1.29,95%CI 1.06-1.56,p=0.0095)。
临床怎么用
- 作者认为,中间型减瘤术不应在超过3-4周期新辅助化疗后进行,手术目标为完全切除。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Interval debulking surgery is recommended after 3-4 cycles (standard IDS) of neoadjuvant chemotherapy (NACT) for epithelial ovarian cancer (EOC) not able to received upfront complete debulking surgery. However, real world practices frequently report performing IDS after ≥5 NAC cycles (delayed IDS). The aim of this work was to evaluate the impact on survival of the number of NACT cycles before IDS. METHODS: We identified from a French national database, women with newly diagnosed EOC who underwent IDS from January 2011 to December 2016. Progression free survival (PFS) and overall survival (OS) were compared using Cox model with adjustments for confounding factors provided by two propensity score methods: inverse probability of treatment weighting (IPTW) and matched-pair analysis. RESULTS: 928 patients treated by IDS for which our propensity score could be applied were identified. After a median follow-up of 49.0 months (95% CI [46.0;52.9]); from the IPTW analysis, median PFS was 17.6 months and 11.5 months (HR = 1.42; CI 95% [1.22-1.67]; p < 0.0001); median OS was 51.2 months and 44.3 months (HR = 1.29; CI 95% [1.06-1.56]; p = 0.0095) for the standard and delayed IDS groups. From the matched-pair analysis (comparing 352 patients for each group), standard IDS was associated with better PFS (HR = 0,77; CI 95% [0.65-0.90]; p = 0.018) but not significantly associated with better OS (HR = 0,84; CI 95% [0.68-1,03]; p = 0.0947). CONCLUSIONS: Carrying IDS after ≥5 NACT cycles seems to have a negative effect on patients survival. The goal of IDS surgery is complete resection and should not be performed after >3-4 NACT cycles.
引用
- Thomas QD, Boussere A, Classe JM, et al. Optimal timing of interval debulking surgery for advanced epithelial ovarian cancer: A retrospective study from the ESME national cohort. Gynecol Oncol. 2022. PMID: 35970603. doi:10.1016/j.ygyno.2022.08.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。